ImmuneScore as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with immune checkpoint inhibitor therapy

Abstract

Aim: Our study aimed to explore the prognostic predictive potential of a novel RNA-based signature called ImmuneScore in advanced non-squamous NSCLC patients receiving combined immune checkpoint inhibitor (ICI) treatment and chemotherapy.

Methods: RNA-sequencing data of 113 patients screened out from ORIENT-11 trial were retrospectively analyzed. ImmuneScore was calculated by the ESTIMATE algorithm. The association of ImmuneScore with early tumor progression, progression-free survival (PFS), and overall survival (OS) was analyzed using chi-square test, Cox regression test, and log-rank test. Receiver operating characteristic (ROC) curves were generated, with higher values of area under the ROC curves (AUCs) indicating better prediction ability.

Results: ImmuneScore was negatively correlated with early tumor progression rate (4.3% vs. 18.6%, P = 0.013) while positively correlated with PFS (HR = 0.29, 95%CI: 0.16-0.53, P < 0.001) and OS (HR = 0.32,95%CI: 0.18-0.58, P < 0.001), demonstrating higher AUCs than that of Programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) (early tumor progression: 0.64 vs. 0.68; PFS: 0.67 vs. 0.58; OS: 0.73 vs. 0.63). Nomograms integrating ImmuneScore and other significant variables (age and T-stage for PFS, gender and T-stage for OS) yielded good performance in PFS and OS prediction.

Conclusion: ImmuneScore serves as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with ICI therapy. Higher ImmuneScore indicates lower early tumor progression rate, longer PFS, and longer OS.

Keywords

Non-squamous non-small cell lung cancer / immune checkpoint inhibitors / RNA-based signature / ImmuneScore

References

[1] Hu X,Chen R.Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.Nat Commun2021;12:687 PMCID:PMC7846738

[2] Yan Y,Finnes H.Combining immune checkpoint inhibitors with conventional cancer therapy.Front Immunol2018;9:1739 PMCID:PMC6072836

[3] Heinhuis KM,Kok M,Beijnen JH.Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.Ann Oncol2019;30:219-35

[4] Rizzo A.Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.Br J Cancer2022;127:1381-2 PMCID:PMC9553978

[5] Bai R,Xu D.Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.Biomark Res2020;8:34 PMCID:PMC7450548

[6] Lei Y,Huang Q,Liu M.Progress and challenges of predictive biomarkers for immune checkpoint blockade.Front Oncol2021;11:617335 PMCID:PMC7992906

[7] Topalian SL,Brahmer JR.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012;366:2443-54 PMCID:PMC3544539

[8] Tang B,Sheng X.Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.J Hematol Oncol2019;12:7 PMCID:PMC6332582

[9] Shen X.Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.BMJ2018;362:k3529 PMCID:PMC6129950

[10] Festino L,Lorigan P.Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection?.Drugs2016;76:925-45

[11] Rizzo A,Giovannelli F.Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis.Cancers2022;14:1404 PMCID:PMC8945985

[12] Santoni M,Mollica V.The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study.Crit Rev Oncol Hematol2022;170:103596

[13] Mollica V,Marchetti A.The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.Clin Exp Med2023;23:5039-49

[14] Jardim DL,de Melo Gagliato D.The challenges of tumor mutational burden as an immunotherapy biomarker.Cancer Cell2021;39:154-73 PMCID:PMC7878292

[15] Strickler JH,Khasraw M.Tumor mutational burden as a predictor of immunotherapy response: is more always better?.Clin Cancer Res2021;27:1236-41 PMCID:PMC9912042

[16] Zeng TM,Yuan ZG,Song YJ.Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.Front Immunol2022;13:943066 PMCID:PMC9501891

[17] Yoshihara K,Martínez E.Inferring tumour purity and stromal and immune cell admixture from expression data.Nat Commun2013;4:2612 PMCID:PMC3826632

[18] Yang Y,Fang J.Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by innovENT anti-PD-1-11).J Thorac Oncol2020;15:1636-46

[19] Yang Y,Wang Z.Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study.J Thorac Oncol2021;16:2109-20

[20] Davis AA.The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors.J Immunother Cancer2019;7:278 PMCID:PMC6815032

[21] Paz-Ares L,Vicente D.KEYNOTE-407 InvestigatorsPembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.N Engl J Med2018;379:2040-51

[22] Gadgeel S,Speranza G.Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.J Clin Oncol2020;38:1505-17

[23] Jeong HY,Lee M.Development of HER2-specific aptamer-drug conjugate for breast cancer therapy.Int J Mol Sci2020;21:9764 PMCID:PMC7767363

[24] Xing X,Jia Y.Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.J Immunother Cancer2022;10:e003984 PMCID:PMC8971786

[25] Cardoso F,Bogaerts J.MINDACT Investigators70-gene signature as an aid to treatment decisions in early-stage breast cancer.N Engl J Med2016;375:717-29

[26] Pitt JM,Eggermont A,Kroemer G.Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.Ann Oncol2016;27:1482-92

[27] Hanoteau A,Krupar R.Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.J Immunother Cancer2019;7:10

[28] Kang Y,Liu Y,Cheng Q.Integrated analysis of immune infiltration features for cervical carcinoma and their associated immunotherapeutic responses.Front Cell Dev Biol2021;9:573497 PMCID:PMC8063060

[29] Cieślik M.Cancer transcriptome profiling at the juncture of clinical translation.Nat Rev Genet2018;19:93-109

[30] Schakenraad A,Twisk J.The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors.Lung Cancer2021;162:36-41

[31] Kim SI,Byrne KT.Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes.Front Immunol2020;11:629722 PMCID:PMC7882695

[32] Erbe R,Wu S.Evaluating the impact of age on immune checkpoint therapy biomarkers.Cell Rep2021;36:109599 PMCID:PMC8757482

[33] Kim J.Determining chemotherapy tolerance in older patients with cancer.J Natl Compr Canc Netw2013;11:1494-502 PMCID:PMC4159075

[34] Conforti F,Bagnardi V.Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.J Natl Cancer Inst2019;111:772-81 PMCID:PMC6695312

[35] Ye Y,Li L.Sex-associated molecular differences for cancer immunotherapy.Nat Commun2020;11:1779 PMCID:PMC7156379

[36] Ma J,Tian Y,Liu B.Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang.Biol Sex Differ2022;13:58 PMCID:PMC9587634

[37] Ulrich BC.Immunotherapy efficacy and gender: discovery in precision medicine.Transl Lung Cancer Res2018;7:S211-3 PMCID:PMC6193899

[38] Atzpodien J,Reitz M.Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.Crit Rev Oncol Hematol2005;55:193-9

[39] Seymour L,Perrone A.RECIST working groupiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.Lancet Oncol2017;18:e143-52 PMCID:PMC5648544

[40] Park HJ,Pyo J.Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis.Radiology2020;297:87-96 PMCID:PMC7526949